Dabrafenib Mesylate

Also known as: Dabrafenib mesylate (GSK-2118436), GSK 2118436 Mesylate, GSK-2118436B, Tafinlar, UNII-B6DC89I63E, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide methanesulfonate (1:1), N-{3-[5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide monomethanesulfonate

Dabrafenib Mesylate (CAS 1195768-06-9) is a compound in the Organic Acids category listed in the Jingsj chemical database. It has the molecular formula C24H24F3N5O5S3 and a molecular weight of 615.668 g/mol. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 1195768-06-9
Jingsj CID: J-1982989-1
Molecular Formula: C₂₄H₂₄F₃N₅O₅S₃
Molecular Weight: 615.668 g/mol
Category: Organic Acids
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Exact Mass	615.089172
PSA	210.96000
LogP	7.03360
Storage Conditions	2-8℃

Activity & Biological Data

Target	BRafV600E:0.6 nM (IC50) CRAF:5 nM (IC50)
Additional Information	[1]. Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther, 2012, 11(4), 909-920. [2]. Lee S, et al. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption. Chem Biol Interact. 2016 Jul 22. [3]. Jung B, et al. Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses. BMB Rep. 2016 Apr;49(4):214-9. [4]. Alexander M Menzies, et al. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012; 6: 391–405. [5]. Posobiec LM, et al. Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation. Birth Defects Res B Dev Reprod Toxicol. 2015 Dec;104(6):244-52.

Target

BRafV600E:0.6 nM (IC50) CRAF:5 nM (IC50)

Additional Information

[1]. Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther, 2012, 11(4), 909-920. [2]. Lee S, et al. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption. Chem Biol Interact. 2016 Jul 22. [3]. Jung B, et al. Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses. BMB Rep. 2016 Apr;49(4):214-9. [4]. Alexander M Menzies, et al. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012; 6: 391–405. [5]. Posobiec LM, et al. Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation. Birth Defects Res B Dev Reprod Toxicol. 2015 Dec;104(6):244-52.

Frequently Asked Questions

What is the CAS number of Dabrafenib Mesylate?

The CAS number of Dabrafenib Mesylate is 1195768-06-9.

What are the molecular formula and molecular weight of Dabrafenib Mesylate?

Dabrafenib Mesylate has molecular formula C24H24F3N5O5S3 and molecular weight 615.668 g/mol.

What are the upstream and downstream products of Dabrafenib Mesylate?

For Dabrafenib Mesylate, Upstream Products: Methanesulfonic acid, Dabrafenib, 2,6-Difluorobenzenesulfonyl chloride.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Dabrafenib Mesylate (CAS 1195768-06-9)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1982989-1 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.